Dachaigh › Leukemia myeloid geur › Maryland › Baltimore
Sgrùdaidhean clionaigeach Leukemia myeloid geur ann an Baltimore, MD
Tha 19 sgrùdaidhean airson Leukemia myeloid geur a’ lorg phàirtichean aig làraichean ann agus timcheall air Baltimore (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
A’ fastadhÌre 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
A’ fastadhÌre 1 tràth
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- agus 2 a bharrachd
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
A’ fastadhÌre 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
A’ fastadhÌre 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
A’ fastadhÌre 1/2
- Johns Hopkins University, Baltimore
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
A’ fastadhÌre 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
A’ fastadhÌre 2
- John Hopkins School of Medicine, Baltimore
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
A’ fastadhÌre 3
- US-Baltimore MD-UMGCCC, Baltimore
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
A’ fastadhÌre 3
- US-Baltimore MD-UMGCCC, Baltimore
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
A’ fastadhÌre 1/2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
A’ fastadhÌre 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
A’ fastadhÌre 1
- Tania Jain, MD, Baltimore
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
A’ fastadhÌre 3
- University of Maryland Medical Center (UMMC), Baltimore
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
A’ fastadhSgrùdadh amharc
- Johns Hopkins, Baltimore
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
A’ fastadhÌre 2
- University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A’ fastadhÌre 1/2
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
A’ fastadhÌre 1
- Johns Hopkins School of Medicine, Baltimore
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
A’ fastadhFàilte do shaor-thoilich fhallain
- Johns Hopkins University, Baltimore
Sgrùdaidhean Leukemia myeloid geur ann am bailtean eile
- Houston, TX85 sgrùdaidhean
- New York City, NY51 sgrùdaidhean
- Boston, MA44 sgrùdaidhean
- Seattle, WA41 sgrùdaidhean
- Baldwin Park, CA40 sgrùdaidhean
- Columbus, OH35 sgrùdaidhean
- Philadelphia, PA34 sgrùdaidhean
- Durham, NC33 sgrùdaidhean
- Atlanta, GA31 sgrùdaidhean
- Tampa, FL29 sgrùdaidhean
- Chicago, IL26 sgrùdaidhean
- Portland, OR25 sgrùdaidhean
Sgrùdaidhean eile ann an Baltimore
- Aillse Sgamhain Neo-chealla-beag60 sgrùdaidhean
- Aillse a' bhroilleach47 sgrùdaidhean
- Aillse Prostata43 sgrùdaidhean
- Ailseachadh nan Sgamhan40 sgrùdaidhean
- Aillse (gach seòrsa)37 sgrùdaidhean
- Cancer Pancreatic31 sgrùdaidhean
- Aillse colorectal31 sgrùdaidhean
- Ailse metastatach28 sgrùdaidhean
- Obesity26 sgrùdaidhean
- Aillse sa bhlaire24 sgrùdaidhean
- Fàilligeadh a' Chridhe24 sgrùdaidhean
- Cancer Ovarian22 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.